Welcome to our dedicated page for Pyxis Oncology news (Ticker: PYXS), a resource for investors and traders seeking the latest updates and insights on Pyxis Oncology stock.
Pyxis Oncology, Inc. (PYXS) is a clinical-stage biopharmaceutical company pioneering antibody-drug conjugates (ADCs) targeting components of the tumor microenvironment to address challenging cancers. This page provides investors and researchers with a comprehensive repository of official announcements, clinical trial updates, and strategic developments.
Access timely updates on PYX-201 progress, partnership agreements, and regulatory milestones. Our curated collection includes earnings reports, preclinical data disclosures, and management commentary – all essential for evaluating the company’s position in oncology innovation.
Key content categories include ADC platform advancements, clinical trial phase transitions, and scientific collaborations. Users will find verified information on therapeutic mechanisms targeting extracellular matrix proteins like EDB+FN, a focus area distinguishing Pyxis in immuno-oncology.
Bookmark this page for streamlined access to material events affecting Pyxis Oncology’s trajectory. Check regularly for new developments in their pipeline programs and evidence-based analysis of therapeutic candidates.
Pyxis Oncology (NASDAQ: PYXS) announced a strategic portfolio prioritization to focus resources on PYX-201, its lead clinical program. PYX-201, a first-in-concept antibody-drug conjugate targeting Extradomain-B Fibronectin, showed promising results in Phase 1 trials with a 50% objective response rate in head and neck squamous cell carcinoma patients and 26% ORR across six solid tumor types.
The company will suspend investment in PYX-106, its second clinical program, to concentrate on PYX-201's development. Multiple expansion studies are planned for early 2025, including monotherapy and combination trials with pembrolizumab. The company's current cash position is expected to fund operations into the second half of 2026.
Pyxis Oncology (NASDAQ: PYXS) announced positive preliminary data from its Phase 1 clinical trial of PYX-201, a novel antibody-drug conjugate targeting Extradomain-B Fibronectin. The drug achieved a 50% objective response rate including one complete response in head and neck cancer patients, and 26% overall response rate across six solid tumor types. PYX-201 demonstrated a favorable safety profile and dose-dependent responses. The company also announced a new clinical trial collaboration with Merck to evaluate PYX-201 in combination with KEYTRUDA®, with dosing expected to begin in Q1 2025.
Pyxis Oncology (NASDAQ: PYXS) reported Q3 2024 financial results and provided updates on its clinical programs. The company ended Q3 with $146.3 million in cash and investments, expecting runway into 2H 2026. The company has enrolled 80 patients in the PYX-201 Phase 1 trial and 45 patients in the PYX-106 trial. Q3 net loss was $21.2 million ($0.35 per share), compared to $23.0 million ($0.56 per share) in Q3 2023. R&D expenses increased to $17.7 million from $14.7 million, while G&A expenses decreased to $6.0 million from $10.7 million year-over-year.
Pyxis Oncology (Nasdaq: PYXS) announced an upcoming investor event on November 20, 2024, to present preliminary data from their Phase 1 clinical trial of PYX-201. The event will be held both in-person in New York City and virtually. The presentation will cover data from approximately 80 patients, including safety, preliminary efficacy, and pharmacokinetics results for PYX-201, a first-in-concept antibody-drug conjugate targeting Extradomain-B Fibronectin in solid tumors. Executive management will be joined by physician thought leaders Dr. Anthony Tolcher and Dr. Glenn Hanna to discuss the findings and future development plans.
Pyxis Oncology (Nasdaq: PYXS), a clinical-stage company developing next-generation cancer therapeutics, has announced its participation in two upcoming investor conferences. CEO Lara S. Sullivan will engage in fireside chats at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 6 at 12:20 PM ET and the H.C. Wainwright 26th Annual Global Investment Conference on September 9 at 2:00 PM ET, both in New York.
Management will also participate in one-on-one meetings during these events. Investors can access live webcasts and replays of the presentations through the Events & Presentations page in the Investor Relations section of Pyxis Oncology's website at ir.pyxisoncology.com.
Pyxis Oncology (PYXS) reported Q2 2024 financial results and provided a corporate update. Key highlights include:
- Preliminary data from PYX-201 Phase 1 trial expected in fall 2024
- Preliminary data from PYX-106 Phase 1 trial expected by year-end 2024
- Cash runway extended into 2H 2026
- $157.2 million in cash and investments as of June 30, 2024
- 72 subjects dosed in PYX-201 trial, 33 in PYX-106 trial
- Q2 2024 R&D expenses: $13.9 million (up from $11.4 million in Q2 2023)
- Q2 2024 net loss: $17.3 million or ($0.29) per share
The company remains focused on developing next-generation therapeutics for difficult-to-treat cancers, with ongoing clinical trials for PYX-201 and PYX-106.
Pyxis Oncology, a clinical stage company developing next-gen cancer therapies, announced its participation in the BTIG Virtual Biotechnology Conference. The event is scheduled for August 5-6, 2024. Lara S. Sullivan, M.D., President and CEO of Pyxis, along with other management members, will engage in one-on-one meetings during the conference.
This participation highlights Pyxis Oncology's commitment to advancing its pipeline of therapeutics targeting difficult-to-treat cancers. The company's presence at this virtual event provides an opportunity for investors and industry professionals to gain insights into Pyxis's ongoing developments and strategic direction in the oncology field.
Pyxis Oncology, a clinical stage company, announced the grant of restricted stock units and stock options to five new employees under its 2022 Inducement Plan. The total grants include 89,530 shares of common stock and options to purchase 111,913 shares at an exercise price of $3.31 per share. These awards, aligned with Nasdaq Listing Rule 5635(c)(4), serve as an inducement for employment and will vest over four years. The initial 25% of the grants will vest on the first anniversary, with the remaining shares vesting monthly over the subsequent three years.
Pyxis Oncology (Nasdaq: PYXS) has appointed Michael A. Metzger to its Board of Directors, effective June 10, 2024. Metzger brings over 25 years of biopharmaceutical experience and is currently the CEO of Syndax Pharmaceuticals. Pyxis CEO Lara S. Sullivan emphasized Metzger's expertise and leadership in innovation as vital for the company's growth, particularly in advancing their antibody-drug conjugates (ADCs) aimed at treating challenging cancers. Metzger expressed enthusiasm for contributing to Pyxis's mission of improving cancer treatment outcomes.
Pyxis Oncology (Nasdaq: PYXS), a clinical-stage company focused on next-generation cancer therapeutics, announced that its President and CEO, Lara S. Sullivan, M.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 6, 2024, at 9:00 AM Eastern Time in New York City. The management team will also hold one-on-one meetings with investors. The event will be webcast live, with a replay available on the company's Investor Relations website.
FAQ
What is the current stock price of Pyxis Oncology (PYXS)?
What is the market cap of Pyxis Oncology (PYXS)?
